上海和香港2021年6月2日 /美通社/ -- 致力于研發和商業化創新腫瘤療法的領先生物制藥公司——德(de)琪醫藥有限公司（簡稱“德(de)琪醫藥”，香(xiang)港(gang)聯交所股(gu)票(piao)代(dai)碼：6996.HK）今日(ri)宣布，同類首款選擇(ze)性(xing)核輸(shu)出抑(yi)制劑(ji)——塞利尼索（selinexor）15項(xiang)研究及成果將在2021年美國臨床腫瘤學(xue)大會(hui)（ASCO）年會(hui)上公布。此屆 ASCO 會(hui)議于6月4日(ri)至6月8日(ri)在線上召開。

線上摘要

Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on RAS-mutated previously treated multiple myeloma (MM).

摘要編號：8027

Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone(Vd) in patients with previously treated multiple myeloma.

摘要編號：8024

Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

摘要編號：8019

Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.

摘(zhai)要編號(hao)：e19037

Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dosedexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).

摘要編號：e20002

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

摘要編號：8018

SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.

摘要編號：TPS5610

Open-label phase 1 study evaluating the tolerability and anti-tumor activity of selinexor and pembrolizumab in colorectal cancer.

摘要(yao)編(bian)號：e15579

A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.

摘要編號：TPS2071

A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.

摘要編號：11534

Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

摘要編號：5565

Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

摘要編號：8038

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.

摘要編號(hao)：TPS8055

Molecular predictors of response to selinexor in advanced unresectable de-differentiated liposarcoma (DDLS).

摘要編號：11509

Selinexor containing regimens in patients with multiple myeloma (MM) previously treated with anti-CD38 monoclonal antibodies (αCD38 mAbs).

摘要(yao)編號：e20020

關于德琪醫藥

德(de)(de)琪醫(yi)藥(yao)有限(xian)公司（簡稱“德(de)(de)琪醫(yi)藥(yao)”，香港聯交所股票代碼：6996.HK）是一家以(yi)研發為驅動的(de)生物(wu)(wu)制藥(yao)領先(xian)企業，致力(li)于(yu)為亞(ya)(ya)太乃至全球患者提供最(zui)領先(xian)的(de)療法，治療腫瘤及其他危及生命(ming)的(de)疾病。自(zi)2017年(nian)正式運(yun)營以(yi)來，德(de)(de)琪醫(yi)藥(yao)通過合作(zuo)引進和自(zi)主(zhu)研發，建立了一條從臨(lin)床(chuang)前到臨(lin)床(chuang)階(jie)段不斷延展的(de)豐富產品(pin)管線。目前，德(de)(de)琪醫(yi)藥(yao)已在多個亞(ya)(ya)太市場獲得15個臨(lin)床(chuang)批(pi)件（IND），并遞交了5個新藥(yao)上市申(shen)請（NDA）。德(de)(de)琪醫(yi)藥(yao)將(jiang)以(yi)“醫(yi)者無疆，創新永續”為愿景，專注于(yu)同(tong)類首款和同(tong)類最(zui)優療法的(de)早(zao)期研發、臨(lin)床(chuang)研究、藥(yao)物(wu)(wu)生產及商業化，解決亟待滿足的(de)臨(lin)床(chuang)需求。